RESUMO
The results of rehabilitative treatment received at health resort by 200 gastric cancer patients were studied. In 85 of them, radioimmunoassay was used to measure serum CEA, ferritin and gastrin levels in the course of treatment. CEA and ferritin concentrations in remission patients (12.6 +/- 5.7 ng/ml and 94,6 +/- 15.3 ng/ml, respectively) differed from those in cases of relapse (69.2 +/- 7.1 ng/ml and 361.4 +/- 46.8 ng/ml). It is suggested that serum markers levels be used as criteria of response to treatment and prognosis.
Assuntos
Biomarcadores Tumorais/sangue , Neoplasias Gástricas/sangue , Adulto , Antígeno Carcinoembrionário/sangue , Ferritinas/sangue , Gastrinas/sangue , Estâncias para Tratamento de Saúde , Humanos , Pessoa de Meia-Idade , Cuidados Pós-Operatórios , Prognóstico , Neoplasias Gástricas/reabilitação , Fatores de TempoAssuntos
Adenocarcinoma/terapia , Ácido Ascórbico/uso terapêutico , Carcinoma/terapia , Fluoruracila/uso terapêutico , Neoplasias Gástricas/terapia , Adulto , Idoso , Terapia Combinada , Feminino , Gastrectomia , Humanos , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Cuidados Pós-Operatórios , Neoplasias Gástricas/mortalidadeRESUMO
The paper deals with the results of treatment of 80 radically operated gastric cancer patients at a rehabilitation gastroenterologic department of a health resort at Morshin. Postresection syndrome frequency in this group was lower than that in controls: loss of weight--15% 27.8% in controls, dumping syndrome--25% 4.6% in controls, reflux-esophagitis--6.3% 9.2% in controls and anemia--11.2% of cases 15.4% in controls. Rehabilitation treatment was particularly effective in cases of gastritis of the stump, anacidity and enterocolitis. Also, it was followed by a greater decrease in the frequency of psychogenic reactions from 65.0 to 15.0% 58.5%--34.1% in controls.
Assuntos
Estâncias para Tratamento de Saúde , Síndromes Pós-Gastrectomia/reabilitação , Neoplasias Gástricas/reabilitação , Adulto , Idoso , Feminino , Gastrectomia/reabilitação , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Gástricas/cirurgia , Ucrânia , Avaliação da Capacidade de TrabalhoAssuntos
Fluoruracila/uso terapêutico , Neoplasias Gástricas/terapia , Adulto , Resistência a Medicamentos , Feminino , Gastrectomia , Humanos , Técnicas In Vitro , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/terapia , Cuidados Pós-Operatórios , Neoplasias Gástricas/mortalidadeRESUMO
Two hundred radical operations on gastric tumor patients were performed in the Lvov oncological centre during 1974-1978. As a result of biochemical studies of gastric tumors some essential alterations were established in the 5FU-6-3H incorporation into the acid soluble fraction and in the activity of alkaline phosphatase in 5FU sensitive and resistant tumors. Additional chemotherapy with 5FU was carried out only for patients with tumors sensitive to the drug, due to it the 5-year survival rate in this group of patients has significantly raised.
Assuntos
Fluoruracila/uso terapêutico , Neoplasias Gástricas/metabolismo , Adulto , Células Cultivadas , Avaliação de Medicamentos , Resistência a Medicamentos , Feminino , Mucosa Gástrica/efeitos dos fármacos , Humanos , Técnicas In Vitro , Masculino , Pessoa de Meia-Idade , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/mortalidadeRESUMO
Eighty one patients were studied for individual susceptibility of gastric tumors to 5-FU as evidenced by endogenic respiration and glycolysis of fresh tumor sections, the main criterion being the suppressed respiration, the accessory one inhibition of glycolysis. Three groups of tumors were differentiated: susceptible (25.9%), slightly susceptible (28.4%) and unsusceptible (45.7%) to 5-fluoruracil. Mostly adenocarcinomas were found in a group of susceptible tumors, scirrhous and colloid cancers -- in an unsusceptible group. A correlation outlined between the results of determining susceptibility in vitro and clinical data enabled to recommend the method of determining susceptibility to 5-FU for clinical application.